Hansa Biopharma appoints Renée Aguiar-Lucander as CEO

Ella Day | April 24, 2025 | Appointment | Research and Development |  CEO, Corporate, Hansa Biopharma, appointment, immunology 

Swedish biopharma company, Hansa Biopharma, has announced the appointment of new chief executive officer (CEO) Renée Aguiar-Lucander, replacing Søren Tulstrup who led the company for seven years.

Aguiar-Lucander has a wealth of experience in senior leadership positions in other biopharma companies, playing key roles in the growth and development of companies. At Calliditas Therapeutics, she served as chief executive officer for seven years. Prior to that, she worked at RAL Capital, Omega Funds and 3i Group.

She will support the development of Hansa’s research into treatments for patients with rare immunological conditions. This R&D programme is based on its IgG-cleaving enzyme technology platform, and has met medical needs in autoimmune disease, gene therapy and transplantation.

Advertisement

Chairman of the board, Peter Nicklin, commented: “With the appointment of Renée as CEO, Hansa is entering a new phase of growth and development. Renée brings extensive experience in both the biopharmaceutical and financial sectors, and her proven leadership will be instrumental in advancing the company’s strategic positioning.”

Additionally, Aguiar-Lucander, said: “I am delighted and honoured to take up the position of CEO of Hansa during these exciting and challenging times.” She added, “I look forward to working with the team and board.”

Ella Day
24/4/25

Related Content

Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis

Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate …

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …

The Gateway to Local Adoption Series

Latest content